Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01202890 · ClinicalTrials.gov registry record · Phase 1
Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer
A Phase 1 study, sponsored by New Mexico Cancer Research Alliance.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT01202890 is a Phase 1 study that was terminated before completion, run by New Mexico Cancer Research Alliance. The registered enrollment target is 1 participants.
The verdict
NCT01202890, a Phase 1 study, was terminated before completion, sponsored by New Mexico Cancer Research Alliance.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This study will test the feasibility of combining 3 drugs, Revlimid with Doxil and Bevacizumab,and gather preliminary data on the potential activity of the combination in patients with platinum resistant/refractory ovarian cancer.
Interventions
- DRUG Lenalidomide, Liposomal Doxorubicin, Bevacizumab
- DRUG Revlimid, Doxil, Avastin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2010-09 |
| Est. Completion | 2012-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01202890
The ClinicalTrials.gov registry entry for NCT01202890 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New Mexico Cancer Research Alliance, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lenalidomide, Liposomal Doxorubicin, Bevacizumab is the first listed.
NCT01202890 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01202890 about?
NCT01202890 is a clinical study titled "Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer". This study will test the feasibility of combining 3 drugs, Revlimid with Doxil and Bevacizumab,and gather preliminary data on the potential activity of the combination in patients with platinum resistant/refractory ovarian cancer.
What is the current status of trial NCT01202890?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2010-09. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01202890?
The interventions under investigation include: Lenalidomide, Liposomal Doxorubicin, Bevacizumab (DRUG), Revlimid, Doxil, Avastin (DRUG).
Who is sponsoring clinical trial NCT01202890?
This trial is sponsored by New Mexico Cancer Research Alliance, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.